FDMT · Insider Trading
4D Molecular Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by FDMT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | David Kirn | See Remarks | Sell | −58,333 | −$753.94K |
| 2026-09-22 | Scott Bizily | Chief Legal Officer | MIXED | — | −$15.55K |
| 2026-09-16 | David Kirn | See Remarks | Sell | −58,333 | −$811.00K |
| 2026-09-03 | Scott Bizily | Chief Legal Officer | MIXED | — | −$4.39K |
| 2026-08-21 | David Kirn | See Remarks | MIXED | −19,076 | −$881.27K |
| 2026-08-17 | Scott Bizily | Chief Legal Officer | MIXED | — | −$26.03K |
| 2026-08-05 | David Kirn | See Remarks | Sell | −26,842 | −$274.60K |
| 2026-08-04 | David Kirn | See Remarks | Sell | −12,415 | −$124.72K |
| 2026-07-14 | David Kirn | See Remarks | Sell | −58,333 | −$737.41K |
| 2026-07-02 | Scott Bizily | Chief Legal Officer | MIXED | — | −$51.22K |
| 2026-06-25 | Scott Bizily | Chief Legal Officer | MIXED | — | −$77.11K |
| 2026-06-23 | David Kirn | See Remarks | Sell | −114,746 | −$1.20M |
| 2026-06-18 | Susannah Gray | Director | A | +50,000 deriv. | — |
| 2026-06-18 | Glenn Sblendorio | Director | A | +50,000 deriv. | — |
| 2026-06-18 | John F Milligan | Director | A | +75,000 deriv. | — |
| 2026-06-18 | Shawn Tomasello | Director | A | +50,000 deriv. | — |
| 2026-06-18 | Charles Theuer | Director | A | +50,000 deriv. | — |
| 2026-06-18 | Jacob Chacko | Director | A | +50,000 deriv. | — |
| 2026-06-18 | Nancy Miller-Rich | Director | A | +50,000 deriv. | — |
| 2026-06-02 | David Kirn | See Remarks | Sell | −1,922 | −$19.26K |
| 2026-03-27 | Scott Bizily | Chief Legal Officer | A | +217,000 deriv. | — |
| 2026-03-27 | David Kirn | Chief Executive Officer | A | +750,000 deriv. | — |
| 2026-03-27 | Christopher Paul Simms | See Remarks | A | +219,000 deriv. | — |
| 2026-03-24 | Ashoo Gupta | VP, Finance and Controller | MIXED | +696 | −$3.36K |
| 2026-01-07 | Glenn Sblendorio | Director | A | +45,000 deriv. | — |
| 2025-12-23 | Ashoo Gupta | VP, Finance and Controller | MIXED | +697 | −$3.38K |
| 2025-12-19 | Scott Bizily | Chief Legal Officer | MIXED | — | −$11.05K |
| 2025-12-16 | Charles Theuer | Director | M | +9,333 | +$10.64K |
| 2025-12-11 | Kristian Humer | Chief Financial Officer | A | +480,000 deriv. | — |
| 2025-11-19 | Scott Bizily | Chief Legal Officer | MIXED | — | −$10.55K |
| 2025-10-27 | Scott Bizily | Chief Legal Officer | MIXED | −1,594 | −$25.10K |
| 2025-10-20 | Scott Bizily | Chief Legal Officer | MIXED | — | −$9.86K |
| 2025-10-14 | Scott Bizily | Chief Legal Officer | Sell | −2,408 | −$24.08K |
| 2025-09-26 | Scott Bizily | Chief Legal Officer | Sell | −2,407 | −$19.26K |
| 2025-06-20 | Nancy Miller-Rich | Director | A | +22,500 deriv. | — |
| 2025-06-20 | Jacob Chacko | Director | A | +22,500 deriv. | — |
| 2025-06-20 | Charles Theuer | Director | A | +22,500 deriv. | — |
| 2025-06-20 | Susannah Gray | Director | A | +22,500 deriv. | — |
| 2025-06-20 | Shawn Tomasello | Director | A | +22,500 deriv. | — |
| 2025-06-20 | John F Milligan | Director | A | +33,750 deriv. | — |
| 2025-03-10 | Scott Bizily | Chief Legal Officer | A | +78,500 deriv. | — |
| 2025-03-10 | Robert Young Kim | Chief Medical Officer | A | +92,300 deriv. | — |
| 2025-03-10 | David Kirn | Chief Executive Officer | A | +267,500 deriv. | — |
| 2025-03-10 | Fariborz Kamal | President & COO | A | +178,400 deriv. | — |
| 2025-03-10 | Uneek Mehra | See Remarks | A | +130,000 deriv. | — |
| 2024-12-10 | RA Capital Healthcare Fund LP | 10%+ Owner | J | −2,140,000 | — |
| 2024-11-13 | BVF I GP LLC | — | J | −56,800,000 | — |
| 2024-09-18 | Scott Bizily | Chief Legal Officer | MIXED | — | −$4.92K |
| 2024-08-21 | Scott Bizily | Chief Legal Officer | MIXED | — | −$4.25K |
| 2024-07-18 | Scott Bizily | Chief Legal Officer | MIXED | — | −$34.15K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| RA Capital Healthcare Fund LP | 10%+ Owner | 4,563,211 | $56.08M |
| David Kirn | See Remarks | 1,309,425 | $16.09M |
| John F Milligan | Director | 100,000 | $1.23M |
| BVF I GP LLC | — | 87,911 | $1.08M |
| Ashoo Gupta | VP, Finance and Controller | 46,914 | $576.57K |
| Charles Theuer | Director | 41,684 | $512.30K |
| Scott Bizily | Chief Legal Officer | 10,252 | $126.00K |
| Robert Young Kim | Chief Medical Officer | 7,595 | $93.34K |
| Fariborz Kamal | President & COO | 4,347 | $53.42K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the FDMT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.